Literature DB >> 28454277

Monocyte-derived dendritic cells from patients with cervical intraepithelial lesions.

Angela Maria Moed Lopes1, Márcia Antoniazi Michelin1,2, Eddie Fernando Cândido Murta1,3.   

Abstract

Immunotherapy with dendritic cells (DCs) is a great promise for the treatment of neoplasms. However, the obtainment and protocol of differentiation of these cells may depend on extrinsic factors such as the tumor itself. The aim of the present study was to verify the influence of cervical neoplasia on different protocols of differentiation of monocyte-derived DCs resulting in an increased maturation phenotype. A total of 83 women were included in the study. The patients were grouped in low-grade squamous intraepithelial lesion (LSIL) (n=30), high-grade squamous intraepithelial lesion (HSIL) (n=22), cervical cancer (n=10) and healthy patients (n=21) groups. The mononuclear cells of patients were subjected to three differentiation protocols. In protocol I (pI), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-4 and tumor necrosis factor (TNF)-α were used for the differentiation of mature DCs (pIDCs). In protocol II (pII), monocytes were stimulated with GM-CSF, IL-4, TNF-α and activated lymphocytes in the absence of non-adherent cells (pIIDCs). In protocol III (pIII), monocytes were stimulated with GM-CSF, IL-4, TNF-α and activated lymphocytes in the presence of non-adherent cells (pIIIDCs). These cells were evaluated by flow cytometry for the expression of maturation markers such as cluster of differentiation (CD)11c, CD86 and human leukocyte antigen-antigen D related (HLA-DR). The main cytokines secreted (IL-4, IL-12 and transforming growth factor-β) were measured by ELISA. Our results indicate a significantly lower mature profile of pIIDCs and a significant increase in CD11c+ pIIIDCs able to produce IL-12 (P=0.0007). Furthermore, a significant reduction in cervical cancer HLA-DR+ pIDCs (P=0.0113) was also observed. HSIL patients exhibited a higher percentage of HLA-DR+ pIIDCs (P=0.0113), while LSIL patients had a lower percentage of CD11c+ pIIIDCs (P=0.0411). These findings suggest that the extent of cervical lesions affects the process of differentiation of DCs. Furthermore, activated lymphocytes may induce a better maturation of monocyte-derived DCs, and the presence of mononuclear cells appears to contribute to the DC differentiation process.

Entities:  

Keywords:  cervical cancer; dendritic cell; immunotherapy; squamous intraepithelial lesion

Year:  2017        PMID: 28454277      PMCID: PMC5403355          DOI: 10.3892/ol.2017.5595

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  44 in total

Review 1.  Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity.

Authors:  Y J Liu
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

2.  Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses.

Authors:  Ralph Mocikat; Heidi Braumüller; Alain Gumy; Oliver Egeter; Heike Ziegler; Uwe Reusch; Anja Bubeck; Jacques Louis; Reinhard Mailhammer; Gert Riethmüller; Ulrich Koszinowski; Martin Röcken
Journal:  Immunity       Date:  2003-10       Impact factor: 31.745

Review 3.  Dendritic cell immunotherapy: mapping the way.

Authors:  Carl G Figdor; I Jolanda M de Vries; W Joost Lesterhuis; Cornelis J M Melief
Journal:  Nat Med       Date:  2004-05       Impact factor: 53.440

Review 4.  Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.

Authors:  Alberto Pinzon-Charry; Tammy Maxwell; J Alejandro López
Journal:  Immunol Cell Biol       Date:  2005-10       Impact factor: 5.126

Review 5.  The 2001 Bethesda System terminology.

Authors:  Barbara S Apgar; Lauren Zoschnick; Thomas C Wright
Journal:  Am Fam Physician       Date:  2003-11-15       Impact factor: 3.292

6.  High-level IL-12 production by human dendritic cells requires two signals.

Authors:  A Snijders; P Kalinski; C M Hilkens; M L Kapsenberg
Journal:  Int Immunol       Date:  1998-11       Impact factor: 4.823

Review 7.  Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.

Authors:  Constantin N Baxevanis; Sonia A Perez; Michael Papamichail
Journal:  Cancer Immunol Immunother       Date:  2008-08-15       Impact factor: 6.968

8.  The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells.

Authors:  Cláudia M Rodrigues; Bruna F Matias; Eddie F C Murta; Márcia A Michelin
Journal:  Clin Med Insights Oncol       Date:  2011-04-25

9.  CD1-mediated gamma/delta T cell maturation of dendritic cells.

Authors:  David S Leslie; Michael S Vincent; Franca M Spada; Hiranmoy Das; Masahiko Sugita; Craig T Morita; Michael B Brenner
Journal:  J Exp Med       Date:  2002-12-16       Impact factor: 14.307

10.  Defective generation and maturation of dendritic cells from monocytes in colorectal cancer patients during the course of disease.

Authors:  Giulia Orsini; Annalisa Legitimo; Alessandra Failli; Paola Ferrari; Andrea Nicolini; Roberto Spisni; Paolo Miccoli; Rita Consolini
Journal:  Int J Mol Sci       Date:  2013-11-07       Impact factor: 5.923

View more
  5 in total

Review 1.  Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment.

Authors:  Rosalia Busà; Matteo Bulati; Ester Badami; Giovanni Zito; Daniela Claudia Maresca; Pier Giulio Conaldi; Giuseppe Ercolano; Angela Ianaro
Journal:  Front Cell Dev Biol       Date:  2022-05-26

2.  [Blocking programmed death-ligand 1 attenuates maturation inhibition of dendritic cells by co-cultured breast cancer cells].

Authors:  Xiao-Ran Yu; Qiao-Sheng Wen; Yi Xiao; Rui Tang; Fu-Xi Li; Wen-Feng Shao; Yan-Lin Yu; Jing-Bo Xiong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-05-20

Review 3.  Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy.

Authors:  Thiago A Patente; Mariana P Pinho; Aline A Oliveira; Gabriela C M Evangelista; Patrícia C Bergami-Santos; José A M Barbuto
Journal:  Front Immunol       Date:  2019-01-21       Impact factor: 7.561

4.  Exosomes from HPV-16 E7-pulsed dendritic cells prevent the migration, M1 polarization, and inflammation of macrophages in cervical cancer by regulating catalase 2 (CAT2).

Authors:  Guangping Zhang; Yanan Liao; Xiaoping Pan; Xiaoli Zhang
Journal:  Ann Transl Med       Date:  2022-02

Review 5.  The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer.

Authors:  Beatriz Subtil; Alessandra Cambi; Daniele V F Tauriello; I Jolanda M de Vries
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.